Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ImmunoCobiVem: Sequencing Targeted Therapy and Immunotherapy in Melanoma
NCT02902029Phase 2Completed
- Sponsor
- Universitätsmedizin Essen
- Start
- Nov 2016
- Primary completion
- Mar 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of atezolizumab, vemurafenib, cobimetinib in melanoma, sponsored by Universitätsmedizin Essen. Started Nov 2016; status: completed.
02
Drugs
atezolizumabvemurafenibcobimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02902029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02902029.